At the 61st ASH Annual Meeting & Exposition, Alexey Danilov discusses his presentation: Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management.
Questions
1. What have been the most important recent advances in the use of BTK inhibitors in B-cell malignancies? (0:05)
2. What factors should be considered when selecting the most appropriate BTK inhibitors for an individual? (1:27)
3. What are the major obstacles to the first-line use of BTK inhibitors in B-cell malignancies and how can these be overcome? (3:12)
4. What are likely to be the future challenges and research directions in the use of BTK inhibitors for B-cell malignancies? (4:50)
Alexey Danilov is a consult for Janssen, Pharmacyclics, AstraZeneca, Beigene, Verastem, Genentech, Gilead, Nurix, Curis and TG Therapeutics. He has received research funding from AstraZeneca, Gilead, Genentech, Verastem, BMS and Bayer.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
